Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05104736 trial (PT-112): what clinicians have said so far
PT-112 in Subjects With Thymoma and Thymic Carcinoma
- NCT05104736 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05104736 (PT-112 in thymoma and thymic carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05104736 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Thymic Epithelial Tumor; Recurrent Thymoma; Thymic Cancer
- Interventions
- PT-112
- Arms
- PT-112 · Experimental
- Enrollment
- 53 (estimated)
- Primary outcomes
- overall response rate (ORR)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Apr 6, 2022
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05104736 · updated Oct 16, 2026